The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Hyperuricemia in Children and Adolescents with Autism Spectrum Disorder Treated with Risperidone: The Risk Factors for Metabolic Adverse Effects
|
|---|---|
| Published in |
Frontiers in Pharmacology, January 2017
|
| DOI | 10.3389/fphar.2016.00527 |
| Pubmed ID | |
| Authors |
Natchaya Vanwong, Pornpen Srisawasdi, Nattawat Ngamsamut, Nopphadol Nuntamool, Apichaya Puangpetch, Bhunnada Chamkrachangpada, Yaowaluck Hongkaew, Penkhae Limsila, Wiranpat Kittitharaphan, Chonlaphat Sukasem |
| Abstract |
Background: Atypical antipsychotics have been found to be associated with hyperuricemia. Risperidone, one of the atypical antipsychotics, might be related to the hyperuricemia among autism spectrum disorder (ASD) patients. The aims of this study were to determine the prevalence of hyperuricemia in ASD patients treated with risperidone and to determine associations between serum uric acid levels and risperidone dosage, treatment duration, and metabolic parameters. Methods: 127 children and adolescents with ASD treated with risperidone and 76 age-matched risperidone-naïve patients with ASD were recruited. The clinical data and laboratory data were analyzed. Hyperuricemia was defined as serum uric acid >5.5 mg/dl. Results: Hyperuricemia was present in 44.70% of risperidone-naïve patients with ASD and 57.50% of ASD patients treated with risperidone. The fasting uric acid levels were significantly higher in the risperidone group than in the risperidone-naïve group (5.70 vs. 5.35 mg/dl, P = 0.01). The increased uric acid concentrations were significantly associated with adolescent patients treated with risperidone. The higher dose of risperidone and/or the longer treatment time were associated with the increased uric acid levels. Uric acid levels significantly rose with body mass index (BMI), waist circumference (WC), triglyceride (TG) levels, triglycerides to high-density lipoprotein cholesterol ratio (TG/HDL-C), insulin levels, homeostatic model assessment index (HOMA-IR), high-sensitivity CRP (hs-CRP) levels, and leptin levels. Conversely, the levels of HDL-C and adiponectin were negatively correlated with uric acid levels. In multiple regression analysis, there were age, BMI, TG/HDL-C ratio, and adiponectin levels remained significantly associated with uric acid levels. Conclusion: Hyperuricemia may play a role in metabolic adverse effect in children and adolescents with ASDs receiving the high dose and/or the long-term treatment with risperidone. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 14% |
| Mexico | 1 | 7% |
| United Kingdom | 1 | 7% |
| Venezuela, Bolivarian Republic of | 1 | 7% |
| Switzerland | 1 | 7% |
| Unknown | 8 | 57% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 93% |
| Practitioners (doctors, other healthcare professionals) | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 34 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 24% |
| Researcher | 6 | 18% |
| Student > Doctoral Student | 3 | 9% |
| Student > Ph. D. Student | 3 | 9% |
| Student > Bachelor | 2 | 6% |
| Other | 5 | 15% |
| Unknown | 7 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 5 | 15% |
| Medicine and Dentistry | 5 | 15% |
| Nursing and Health Professions | 3 | 9% |
| Agricultural and Biological Sciences | 3 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Other | 8 | 24% |
| Unknown | 8 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 February 2017.
All research outputs
#2,233,433
of 25,654,806 outputs
Outputs from Frontiers in Pharmacology
#931
of 19,993 outputs
Outputs of similar age
#43,718
of 423,406 outputs
Outputs of similar age from Frontiers in Pharmacology
#12
of 172 outputs
Altmetric has tracked 25,654,806 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 19,993 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 423,406 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 172 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.